| [Objective]1By comparing the received neoadjuvant chemotherapy breast cancer4cycles and6cycles of different patients, and the expression of ER, PR, Cerb-B2, Ki-67change, the effect of neoadjuvant chemotherapy on4or6cycle of treatment of breast cancer.[Method]1Group:4cycle group after42cases of pathologically confirmed breast cancer patients with4cycles of adjuvant chemotherapy.6cycle group after45cycles of neoadjuvant chemotherapy in6patients with pathologically confirmed breast cancer patients.2Comparison of2breast cancer4,6cycles of neoadjuvant chemotherapy: through the statistical analysis of4patients with breast cancer after6cycles of chemotherapy, the clinical remission rate, comparing the effect of4patients with breast cancer,6cycles of neoadjuvant chemotherapy.3Of4breast cancer,6cycles of neoadjuvant and expression changes of ER, PR, Cerb-B2and Ki-67contrast:the expression of ER, PR, Cerb-B2and Ki-67before and after chemotherapy in patients with breast cancer by statistical analysis, the influence of different cycles of chemotherapy on expression of ER, PR, Cerb-B2and Ki-67.4Statistical analysis:the results using the SPSS statistical software package for statistical analysis of17. [Result]1Effect of neoadjuvant chemotherapy in1patients with breast cancer(1)37of7patients completed4cycles of neoadjuvant chemotherapy achieved complete remission (CR), accounting for18.91%of the number of subjects (7/37);22patients had partial remission ((PR), accounting for59.45%of the number of subjects (22/37);7patients with disease stabilization (SD), accounted for try the number16.21%(7/37);1patients progressed disease (PD), accounting for2.70%of the number of subjects (1/37), the clinical total effective rate was78.38%(29/37), total yield reached97.30%(36/37). Among them7patients achieved complete remission (pCR) disease now accounts for13.51%of the number of subjects,(5/37).(2)42patients before chemotherapy completion of neoadjuvant chemotherapy6cycles of9cases achieved complete remission (CR), accounting for21.43%of the number of subjects (9/42);23patients had partial remission (PR), accounting for54.76%of the number of subjects (23/42);8patients with disease stabilization (SD), accounting for the number of19.05%(8/42);2patients progressed disease (PD), accounting for4.76%of the number of subjects (2/42), the clinical total effective rate was76.19%(32/42), total yield reached95.24%(40/42). Among them7patients achieved complete remission (pCR) disease now accounts for16.67%of the number of subjects,(7/42).(3) The effective rate374cycle group of patients with breast cancer to neoadjuvant chemotherapy was78.37%, effective rate426cycles of neoadjuvant chemotherapy group was76.19%, there was no statistically significant difference (χ2=0.054, P>0.05, p=0.817), no significant difference between the patients with breast cancer neoadjuvant chemotherapy is4cycles and6cycles of neoadjuvant therapy effect.2.The expression changes of ER before and after neoadjuvant chemotherapy for2patients with breast cancer(1)37with4cycles of neo-adjuvant chemotherapy group of breast cancer patients after ER positive expression of the effective rate of chemotherapy was77.27%, the effective rate of ER negative expression patients was80%, no significant difference, P>0.05(χ2=0.039, P=0.843).(2)42with6cycles of neo-adjuvant chemotherapy group of breast cancer patients after ER positive expression of the effective rate of chemotherapy was79.31%, the effective rate of ER negative expression patients was69.23%, no significant difference, P>0.05(χ2=0.2.463, P=0.117).(3) The expression of ER in patients with breast cancer were4cycle group after neoadjuvant chemotherapy in the effective rate of chemotherapy was77.27%,6cycle group after neoadjuvant chemotherapy in the effective rate of chemotherapy was79.31%, there was no statistically significant difference (χ2=0.031, P>0.05, P=0.861).(4) The expression of ER in patients with breast cancer were4cycle group after neoadjuvant chemotherapy in the effective rate of chemotherapy was80%,6cycles of neoadjuvant chemotherapy after the effective rate of chemotherapy was69.23%, no significant difference, P>0.05(χ2=0.431, P=0.512), no significant difference of ER in patients with breast cancer was positive in4cycles group and the6cycle group after neoadjuvant chemotherapy efficacy.3Changes of PR before and after neoadjuvant chemotherapy for3patients with breast cancer(1) The positive expression of breast cancer patients with4cycles of neoadjuvant chemotherapy of PR group the effective rate of chemotherapy was76.19%, the effective rate of ER negative expression patients was81.25%, no significant difference, P>0.05(/=0.137, P=0.711).(2) The positive expression of breast cancer patients with6cycles of neoadjuvant chemotherapy of PR group the effective rate of chemotherapy was79.31%, the effective rate of ER negative expression patients was69.23%, no significant difference, P>0.05(χ2=0.503, P=0.487).(3) The expression of PR in patients with breast cancer were4cycle group after neoadjuvant chemotherapy in the effective rate of chemotherapy was76.19%,6cycle group after neoadjuvant chemotherapy in the effective rate of chemotherapy was79.31%, there was no statistically significant difference (χ2=0.069, P>0.05, P=0.793).(4) The expression of PR in patients with breast cancer were4cycle group after neoadjuvant chemotherapy in the effective rate of chemotherapy was81.25%,6cycle group after neoadjuvant chemotherapy in the effective rate of chemotherapy was69.23%, there was no statistically significant difference (χ2=0.566, P>0.05, P=0.452).4.The expression changes of Cerb-B2before and after neoadjuvant chemotherapy for4patients with breast cancer(1) The positive expression of breast cancer patients with4cycles of neoadjuvant chemotherapy of Cerb-B2group the effective rate of chemotherapy was81.81%, the effective rate of Cerb-B2negative expression patients was50%, the difference was not statistically significant, P>0.05(χ2=2.131, P=0.144).(2) The positive expression of breast cancer patients with6cycles of neoadjuvant chemotherapy of Cerb-B2group the effective rate of chemotherapy was75%, the effective rate of Cerb-B2negative expression patients was100%, the difference was not statistically significant, P>0.05(χ2=0.656, P=0.418).(3) The expression of Cerb-B2in patients with breast cancer were4cycle group after neoadjuvant chemotherapy in the effective rate of chemotherapy was81.81%,6cycle group after neoadjuvant chemotherapy in the effective rate of chemotherapy was75%, there was no statistically significant difference (χ2=0.491, P>0.05, P=0.483).(4) The expression of Cerb-B2in patients with breast cancer were4cycle group after neoadjuvant chemotherapy in the effective rate of chemotherapy was50%,6cycle group after neoadjuvant chemotherapy in the effective rate of chemotherapy was100%, there was no statistically significant difference (χ2=0.889, P>0.05, P=0.346).[Conclusion]1The curative effect of chemotherapy1.137breast cancer patients with1in this experiment, the curative effect of neoadjuvant chemotherapy4cycles and42after6cycles of neoadjuvant chemotherapy efficacy compared no significant difference.1.2This experiment before neoadjuvant chemotherapy in breast cancer patients with positive expression of ER neoadjuvant chemotherapy neoadjuvant chemotherapy for4cycles and6cycles chemotherapy efficacy compared no significant difference. On chemotherapy in patients with ER negative expression in4,6period of efficacy and no obvious statistical difference.1.3This experiment before neoadjuvant chemotherapy in breast cancer patients with positive expression of PR neoadjuvant chemotherapy neoadjuvant chemotherapy for4cycles and6cycles chemotherapy efficacy compared no significant difference. On chemotherapy in patients with PR negative expression in4,6period of efficacy and no obvious statistical difference.1.4This experiment before neoadjuvant chemotherapy in breast cancer patients with positive expression of CerbB-2neoadjuvant chemotherapy neoadjuvant chemotherapy for4cycles and6cycles chemotherapy efficacy compared no significant difference. On chemotherapy in patients with CerbB-2negative expression in4,6period of efficacy and no obvious statistical difference.1.5The curative effect of chemotherapy on expression of Ki-67neoadjuvant chemotherapy in breast cancer patients. In this experiment,4cycles and6cycles of neoadjuvant chemotherapy in breast cancer tissue were positive negative high. Neoadjuvant chemotherapy of Ki-67expression in breast cancer patients with positive new adjuvant chemotherapy for4cycles after6cycles of chemotherapy and chemotherapy efficacy compared no significant difference. On chemotherapy in patients with Ki-67negative expression in4,6period of efficacy and no obvious statistical difference.2The level of expression analysis of2ER, PR, CerbB-2, Ki-672.1In this experiment, the expression level changes of patients before and after chemotherapy,6of4cycles of neoadjuvant chemotherapy in breast cancer ER were not obvious, not to support it as biological factor to predict the effect of neoadjuvant chemotherapy for breast cancer. Comparison of neoadjuvant chemotherapy neoadjuvant chemotherapy for4cycles and6cycles in patients with the expression level of ER, the results have no significant statistical difference.2.2In this experiment, the expression level changes of patients before and after chemotherapy,6of4cycles of neoadjuvant chemotherapy in breast cancer PR were not obvious, not to support it as biological factor to predict the effect of neoadjuvant chemotherapy for breast cancer. Comparison of neoadjuvant chemotherapy neoadjuvant chemotherapy for4cycles and6cycles in patients with the expression level of PR, the results have no significant statistical difference.2.3Changes in expression levels of CerbB-2in this experiment, the4patients before and after chemotherapy,6cycles of neoadjuvant chemotherapy in breast cancer are not obvious, not to support it as biological factor to predict the effect of neoadjuvant chemotherapy for breast cancer. Comparison of neoadjuvant chemotherapy neoadjuvant chemotherapy for4cycles and6cycles in patients with the expression level of CerbB-2, the results have no significant statistical difference.2.4In this experiment, bank4,6cycles of neoadjuvant chemotherapy of Ki-67index decreased. |
PDF Full Text Request